Nkgen Biotech, INC 8-K filings

NKGen Biotech received a notice from Nasdaq for not meeting the minimum requirements for independent directors on its board and audit committee following a recent resignation.

NKGen Biotech has entered into a binding term sheet with Meteora Capital, amending a previous warrant agreement to facilitate a share exchange and secure additional financing.

NKGen Biotech announces the resignation of director Alana McNulty, effective February 4, 2024, leading to a temporary reduction in the board size.

NKGen Biotech has amended its forward purchase agreement, increasing the prepayment shortfall and adjusting the terms for share sales.

NKGen Biotech has amended its forward purchase agreement, increasing the prepayment shortfall by $500,000 and adjusting the shortfall consideration.